Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aptevo Therapeutics Inc. (APVO : NSDQ)
 
 • Company Description   
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.

Number of Employees: 54

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.83 Daily Weekly Monthly
20 Day Moving Average: 38,152 shares
Shares Outstanding: 5.01 (millions)
Market Capitalization: $24.18 (millions)
Beta: 6.36
52 Week High: $31.76
52 Week Low: $3.45
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.33% 15.26%
12 Week -7.47% 1.73%
Year To Date -38.63% -25.01%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2401 4TH AVENUE SUITE 1050
-
SEATTLE,WA 98121
USA
ph: 206-838-0500
fax: 206-838-0503
ir@apvo.com http://www.aptevotherapeutics.com
 
 • General Corporate Information   
Officers
Marvin L. White - President; Chief Executive Officer
Fuad El-Hibri - Chairman of the Board of Directors
Jeffrey Lamothe - Executive Vice President and Chief Financial Offic
Daniel J. Abdun-Nabi - Director
Barbara Lopez Kunz - Director

Peer Information
Aptevo Therapeutics Inc. (CORR.)
Aptevo Therapeutics Inc. (RSPI)
Aptevo Therapeutics Inc. (CGXP)
Aptevo Therapeutics Inc. (BGEN)
Aptevo Therapeutics Inc. (GTBP)
Aptevo Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03835L207
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 5.01
Most Recent Split Date: 3.00 (0.07:1)
Beta: 6.36
Market Capitalization: $24.18 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.33 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-6.24 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 1.86
EPS Growth
vs. Year Ago Period: 8.62%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 28.62%
vs. Previous Quarter: -15.03%
ROE
03/31/22 - -717.67
12/31/21 - -357.62
09/30/21 - -248.45
ROA
03/31/22 - -49.92
12/31/21 - -45.10
09/30/21 - -46.52
Current Ratio
03/31/22 - 1.75
12/31/21 - 1.51
09/30/21 - 1.82
Quick Ratio
03/31/22 - 1.75
12/31/21 - 1.51
09/30/21 - 1.82
Operating Margin
03/31/22 - -228.05
12/31/21 - -239.24
09/30/21 - -272.56
Net Margin
03/31/22 - -222.55
12/31/21 - -231.51
09/30/21 - -265.80
Pre-Tax Margin
03/31/22 - -228.05
12/31/21 - -239.24
09/30/21 - -272.56
Book Value
03/31/22 - -1.18
12/31/21 - 0.25
09/30/21 - 1.49
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 3.05
09/30/21 - 0.55
Debt-to-Capital
03/31/22 - -
12/31/21 - 75.30
09/30/21 - 35.49
 

Powered by Zacks Investment Research ©